Targeting NLRP3 inflammasome to reduce steatosis, sterile liver inflammation, and consequent fibrosis may be an underlying mechanism for the therapeutic action of FTZ on NASH and possibly on other end-organ damage induced by metabolic syndrome. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.